Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Other financing activities (2017 - 2025)

Immucell (ICCC) has disclosed Other financing activities for 14 consecutive years, with $24905.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other financing activities fell 84.41% year-over-year to $24905.0, compared with a TTM value of -$202723.0 through Sep 2025, down 195.19%, and an annual FY2024 reading of $5037.0, down 85.78% over the prior year.
  • Other financing activities was $24905.0 for Q2 2025 at Immucell, down from $42975.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $159765.0 in Q2 2024 and bottomed at -$270603.0 in Q4 2024.
  • Average Other financing activities over 5 years is $20219.3, with a median of $33940.0 recorded in 2025.
  • The sharpest move saw Other financing activities tumbled 331.77% in 2024, then surged 753.19% in 2025.
  • Year by year, Other financing activities stood at $78430.0 in 2021, then plummeted by 85.88% to $11075.0 in 2022, then plummeted by 665.9% to -$62673.0 in 2023, then crashed by 331.77% to -$270603.0 in 2024, then surged by 109.2% to $24905.0 in 2025.
  • Business Quant data shows Other financing activities for ICCC at $24905.0 in Q2 2025, $42975.0 in Q1 2025, and -$270603.0 in Q4 2024.